EU Off-Patent Industry Sees ‘Limited Immediate Risk’ From COVID-19

But Coronavirus Could Have ‘Important Impact’ If Situation Continues

 The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.

Mask
Medicines for Europe sees a limited immediate risk from the coronavirus outbreak, but the situation could worsen • Source: Shutterstock

Europe’s off-patent industry sees a “limited immediate risk to production or supplies in Europe” as a result of the coronavirus COVID-19 outbreak, according to a letter submitted by industry association Medicines for Europe to the European Medicines Agency.

However, the letter from Medicines for Europe director general Adrian van den Hoven acknowledges, if the situation continues and...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Manufacturing

More from Business